Somatic MED12 mutations in uterine leiomyosarcoma and colorectal cancer

British Journal of Cancer

Volumn 107, Issue 10, 2012, Pages 1761-1765

  Kampjarvi K ^a   Makinen N ^a   Kilpivaara, O ^a   Arola, J ^a   Heinonen, H R ^a   Bohm J ^b   Abdel Wahab, O ^c   Lehtonen, H J ^a   Pelttari, L M ^a   Mehine, M ^a   Schrewe, H ^d   Nevanlinna, H ^a   Levine, R L ^c   Hokland, P ^e   Bohling T ^a   Mecklin, J P ^f   Butzow R ^a   Aaltonen, L A ^a   Vahteristo, P ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b JYVÄSKYLÄ CENTRAL HOSPITAL   (Finland)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d MAX PLANCK INSTITUTE FOR MOLECULAR GENETICS   (Germany)

^e AARHUS UNIVERSITY HOSPITAL   (Denmark)

^f UNIVERSITY OF EASTERN FINLAND   (Finland)

Author keywords

Benign tumours; Malignant tumours; MED12; Mutation screening; Somatic mutation

Indexed keywords

ARTICLE; COLORECTAL CANCER; EXON; GENE; GENETIC SCREENING; HUMAN; HUMAN TISSUE; MED 12 GENE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; SOMATIC MUTATION; UTERUS SARCOMA;

COLORECTAL NEOPLASMS; EXOME; EXONS; FEMALE; HUMANS; LEIOMYOMA; LEIOMYOSARCOMA; MEDIATOR COMPLEX; MUTATION; SEQUENCE ANALYSIS, DNA; UTERINE NEOPLASMS;

EID: 84869029053     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.428     Document Type: Article

References (22)

1. Barbieri CE, Baca SC, Lawrence MS, Demichelis F, Blattner M, Theurillat JP, White TA, Stojanov P, Van Allen E, Stransky N, Nickerson E, Chae SS, Boysen G, Auclair D, Onofrio RC, Park K, Kitabayashi N, MacDonald TY, Sheikh K, Vuong T, Guiducci C, Cibulskis K, Sivachenko A, Carter SL, Saksena G, Voet D, Hussain WM, Ramos AH, Winckler W, Redman MC, Ardlie K, Tewari AK, Mosquera JM, Rupp N, Wild PJ, Moch H, Morrissey C, Nelson PS, Kantoff PW, Gabriel SB, Golub TR, Meyerson M, Lander ES, Getz G, Rubin MA, Garraway LA (2012) Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet 44: 685-689.
2. The Cancer Genome Atlas Network (2012) Comprehensive molecular characterization of human colon and rectal cancer. Nature 487: 330-337.
3. Christacos NC, Quade BJ, Dal Cin P, Morton CC (2006) Uterine leiomyomata with deletions of Ip represent a distinct cytogenetic subgroup associated with unusual histologic features. Genes Chromosomes Cancer 45: 304-312. (Pubitemid 43238480)
4. Dave UP, Akagi K, Tripathi R, Cleveland SM, Thompson MA, Yi M, Stephens R, Downing JR, Jenkins NA, Copeland NG (2009) Murine leukemias with retroviral insertions at Lmo2 are predictive of the leukemias induced in SCID-X1 patients following retroviral gene therapy. PLoS Genet 5: e1000491.
5. Day Baird D, Dunson DB, Hill MC, Cousins D, Schectman JM (2003) High cumulative incidence of uterine leiomyoma in black and white women: ultrasound evidence. Am J Obstet Gynecol 188: 100-107. (Pubitemid 36135604)
6. Galbraith MD, Donner AJ, Espinosa JM (2010) CDK8: A positive regulator of transcription. Transcription 1: 4-12.
7. Gobert V, Osman D, Bras S, Auge B, Boube M, Bourbon HM, Horn T, Boutros M, Haenlin M, Waltzer L (2010) A genome-wide RNA interference screen identifies a differential role of the mediator CDK8. module subunits for GATA/RUNX-Activated transcription in Drosophila. Mol Cell Biol 30: 2837-2848.
8. Je EM, Kim MR, Min KO, Yoo NJ, Lee SH (2012) Mutational analysis of MED12 exon 2 in uterine leiomyoma and other common tumors. Int J Cancer 131(6): E1044-E1047.
9. Keightley MC, Layton JE, Hayman JW, Heath JK, Lieschke GJ (2011) Mediator subunit 12 is required for neutrophil development in zebrafish. PLoS One 6: e23845.
10. Kilpinen S, Autio R, Ojala K, Iljin K, Bucher E, Sara H, Pisto T, Saarela M, Skotheim RI, Bjorkman M, Mpindi JP, Haapa-Paananen S, Vainio P, Edgren H, Wolf M, Astola J, Nees M, Hautaniemi S, Kallioniemi O (2008) Systematic bioinformatic analysis of expression levels of 17 330 human genes across 9783 samples from 175 types of healthy and pathological tissues. Genome Biol 9: R139.
11. Kim S, Xu X, Hecht A, Boyer TG (2006) Mediator is a transducer of Wnt/beta-catenin signaling. J Biol Chem 281: 14066-14075.
12. Knuesel MT, Meyer KD, Donner AJ, Espinosa JM, Taatjes DJ (2009) The human CDK8 subcomplex is a histone kinase that requires Med12 for activity and can function independently of mediator. Mol Cell Biol 29: 650-661.
13. Markowski DN, Bartnitzke S, Loning T, Drieschner N, Helmke BM, Bullerdiek J (2012) MED12 mutations in uterine fibroids-their relationship to cytogenetic subgroups. Int J Cancer 131(7): 1528-1536.
14. McGuire MM, Yatsenko A, Hoffner L, Jones M, Surti U, Rajkovic A (2012) Whole exome sequencing in a random sample of North American women with leiomyomas identifies MED12 mutations in majority of uterine leiomyomas. PLoS One 7: e33251.
15. Mitelman F (1998) Catalog of chromosomal aberration in cancer. Wiley Liss: New York Mäkinen N, Heinonen HR, Moore S, Tomlinson IP, van der Spuy ZM, Aaltonen LA (2011b) MED12 exon 2 mutations are common in uterine leiomyomas from South African patients. Oncotarget 2: 966-969.
16. Mäkinen N, Mehine M, Tolvanen J, Kaasinen E, Li Y, Lehtonen HJ Gentile M, Yan J, Enge M, Taipale M, Aavikko M, Katainen R Virolainen E, Böhling T, Koski TA, Launonen V, Sjöberg J, Taipale J, Vahteristo P, Aaltonen LA (2011a) MED12, the mediator complex subunit 12 gene, is mutated at high frequency in uterine leiomyomas. Science 334: 252-255.
17. Parker WH (2007) Etiology, symptomatology, and diagnosis of uterine myomas. Fertil Steril 87: 725-736. (Pubitemid 46553757)
18. Pe'rot G, Croce S, Ribeiro A, Lagarde P, Velasco V, Neuville A, Coindre JM, Stoeckle E, Floquet A, Macgrogan G, Chibon F (2012) MED12 alterations in both human benign and malignant uterine soft tissue tumors. PLoS One 7: e40015.
19. Polakis P (2000) Wnt signaling and cancer. Genes Dev 14: 1837-1851. (Pubitemid 30639518)
20. Rocha PP, Scholze M, Bleiss W, Schrewe H (2010) Med12 is essential for early mouse development and for canonical Wnt and Wnt/PCP signaling. Development 137: 2723-2731.
21. Taatjes DJ (2010) The human Mediator complex: A versatile, genome-wide regulator of transcription. Trends Biochem Sci 35: 315-322.
22. Tallini G, Vanni R, Manfioletti G, Kazmierczak B, Faa G, Pauwels P, Bullerdiek J, Giancotti V, Van Den Berghe H, Dal Cin P (2000) HMGI-C and HMGI(Y) immunoreactivity correlates with cytogenetic abnormalities in lipomas, pulmonary chondroid hamartomas, endometrial polyps, and uterine leiomyomas and is compatible with rearrangement of the HMGI-C and HMGI(Y) genes. Lab Invest 80: 359-369(Pubitemid 30167795)